JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shirley, J. T.
Right arrow Articles by Cheng, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shirley, J. T.
Right arrow Articles by Cheng, J. B.

Competition of leukotrienes and ICI-198,615 for [3H]LTD4 binding sites in guinea pig lung membranes suggests the involvement of two LTD4 receptor subtypes

JT Shirley and JB Cheng

Department of Immunology and Infectious Diseases, Pfizer Inc., Groton, Connecticut.

Pharmacological analysis of the effects of leukotriene D4 (LTD4) antagonists on contraction of guinea pig airway smooth muscle to leukotrienes reveals the presence of two subtypes of the LTD4 receptor. This finding is, however, inconsistent with [3H]LTD4 equilibrium binding results, which show no evidence of a heterogeneity of pulmonary [3H]LTD4 binding sites. It is possible that LTD4 binds to the two receptor subsets with equal affinity, and the pharmacological difference between them lies in the relative ability of leukotriene (LT) agonists and antagonists to interact at the receptor sites. This study was, therefore, undertaken to determine the rank order of potency of LTs and ICI-198,615 in competing with [3H]LTD4 for their respective binding sites in guinea pig lung membranes. To determine precisely the inhibitory constant (Ki) of LTC4, we used the irreversible gamma- glutamyl transpeptidase inhibitor, acivicin (AT-125), to prevent LTC4 metabolism. Incubation of lung membranes with 5 mM AT-125 for 120 min at 25 degrees C resulted in greater than 98% recovery of LTC4. Unlike L- serine-borate complex, AT-125 failed to inhibit pulmonary [3H]LTD4 binding. These results suggest that AT-125 can be used in this study. Nonlinear least squares analysis of the results of LTD4/[3H]LTD4 or ICI- 198,615/[3H]LTD4 competitive binding reveals that either LTD4 (Ki = 0.49 nM) or ICI-198,615 (Ki = 6.89 nM) interacts at a single homogenous population of [3H]LTD4 binding sites. However, the data of competitive binding results of LTC4 (in the presence of AT-125) or LTE4 are best fitted for its interaction with high- and low-affinity [3H]LTD4 binding sites, designated as LTD4 alpha and LTD4 beta sites, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 258, Issue 2, pp. 531-536, 08/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
C. Brink, S.-E. Dahlen, J. Drazen, J. F. Evans, D. W. P. Hay, S. Nicosia, C. N. Serhan, T. Shimizu, and T. Yokomizo
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
Pharmacol. Rev., March 1, 2003; 55(1): 195 - 227.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Allen, M. Dashwood, K. Morrison, and M. Yacoub
Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries
Circulation, June 23, 1998; 97(24): 2406 - 2413.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.